Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Obesity is a growing concern worldwide, including in low- and middle-income countries (LMICs). Addressing this issue involves various strategies, including dietary and lifestyle changes, medical ...

Whoopi Goldberg made it clear she had no involvement with the promotion of any kind of products and warned fans against ...

A small percentage of patients taking GLP-1 medications have experienced vision problems, but a direct causal link with the ...

The EGOT winner railed against an ad that's circulating on social media with a manipulated version of her promoting "bad ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

"The View" co-host Whoopi Goldberg addressed a "phony weight loss ad" circulating on Instagram during the show on Wednesday ...

Eli Lilly will announce Q4 2024 results, with analysts estimating $13.7 billion in sales and $4.94 EPS, alongside a revenue growth outlook for 2024.

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

Physician–scientists at the University of Utah's John A. Moran Eye Center have published an investigatory review of nine patients who experienced vision complications while taking popular semaglutide ...